Idexx Laboratories (IDXX) Receivables (2009 - 2026)

Idexx Laboratories (IDXX) has reported Receivables for 18 consecutive years, with $922.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 18.2% year-over-year to $922.2 million; the TTM figure through Mar 2026 stood at $922.2 million (up 18.2% YoY), while the FY2025 annual figure was $865.1 million, up 20.17% from the prior year.
• Receivables came in at $922.2 million for Q1 2026 at Idexx Laboratories, up from $865.1 million in the prior quarter.
• The five-year high for Receivables was $922.2 million in Q1 2026, with the low at $571.8 million in Q3 2022.
• Average Receivables over 5 years is $719.7 million, with a median of $719.9 million recorded in 2024.
• Across the five-year window, Receivables increased 5.78% in 2024 and rose 20.17% in 2025, its largest moves.
• Year by year, Receivables stood at $591.4 million in 2022, then climbed by 15.07% to $680.5 million in 2023, then rose by 5.78% to $719.9 million in 2024, then climbed by 20.17% to $865.1 million in 2025, then grew by 6.61% to $922.2 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $922.2 million, $865.1 million, and $855.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.